Center for Health Quality, Outcomes, and Economic Research, VA Medical Center, Bedford, Massachusetts (Drs Selim and Kazis and Ms Qian); Health Outcomes Unit and the Center for the Assessment of Pharmaceutical Practices, and the Department of Health Law, Policy and Management, Boston University School of Public Health, Massachusetts (Drs Selim, Rogers, and Kazis and Mss Simmons and Sonis); Section of General Internal Medicine and Emergency Services, Boston VA Health Care System, West Roxbury, Massachusetts, and Boston University School of Medicine Massachusetts (Dr Selim); FDA Center for Biologics Evaluation and Research, Silver Spring, Maryland (Dr Arya); and McGill University, Montreal, Quebec, Canada (Dr Shapiro).
Correspondence: Lewis E. Kazis, ScD, Center for the Assessment of Pharmaceutical Practices, Department of Health Policy and Management, Boston University School of Public Health, 715 Albany St, T3W, Boston MA 02118 ([email protected]).
The research in this article was supported in part by the Health Outcomes Unit/formerly called Center for the Assessment of Pharmaceutical Practices (CAPP, est. 2000), Boston University School of Public Health, Boston, Massachusetts, and Center for Healthcare Organization and Implementation Research, Veterans Administration Medical Center, Bedford, Massachusetts.This article was written/reviewed by Dr. Deepa Arya in her private capacity. The views expressed in this article/speech do not represent the views of or endorsement by the US Government or the FDA.SF-36 and SF-12 are registered trademarks of the Medical Outcomes Trust. VR-36 and VR-12 are copyright by Trustees of Boston University. All rights reserved.The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.
